Michael has extensive experience in Drug Discovery and Development. Before joining Acousia he served as CSO of the Munich Biotech company Affectis and successfully licensed out two programs in CNS diseases. He held several positions in Medicinal Chemistry at Roche in Basel and Nutley, NJ, USA focusing on CNS disease and Boehringer Ingelheim where he headed the MedChem department in virology research in Laval, Canada. Under his leadership 6 compounds targeting HCV and HIV were granted start of development. He received his PhD in medicinal chemistry from the University of Vienna and did his postdoctoral studies at the ETH Zurich and at Colorado State University in Fort Collins, USA.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Acousia Therapeutics | CSO | — | — | Detail |